Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that the Company's wholly-owned subsidiary, Securedose Synthetics Inc. ("SecureDose") has signed an Letter of Intent ("LOI") on the 16th of May, 2024 with a Canadian controlled drug substance licensed dealer. The Letter of Intent allows for the company to initiate full GMP manufacturing once it has finalized the process development for its novel cocaine manufacturing process. The Company will begin technology transfer for SecureDose's provisionally patented novel Cocaine synthesis method with a goal to ultimately enter into a full agreement for the manufacturing and distribution of biosynthetic pharmaceutical grade cocaine. The identity of the Licensed Dealer is being withheld at this time for business reasons.

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is fifty-one percent (51%) owned by PharmaDrug and fourty-nine percent (49%) owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), has submitted to the Australian Human Research Ethics Committee for review and potential approval to initiate a Phase 1 clinical study (the "Study") of Sairiyo's patented reformulated enteric coated version of orally bioavailable cepharanthine ("PD-001") as a potential treatment for infectious diseases and oncology.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and...

Toronto, Ontario--(Newsfile Corp. - May 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs is pleased to provide a Corporate update from CEO, Robert Steen, to outline its forward strategic and tactical plan to move its patent pending novel manufacturing method for the commercial-scale manufacture of biosynthetic cocaine to support safe supply programs.

Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce today the appointment of Zalman Goldman to the board of directors, subject to approval of the Canadian Securities Exchange.

Toronto, Ontario--(Newsfile Corp. - May 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is fifty-one percent (51%) owned by PharmaDrug and fourty-nine percent (49%) owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), has completed its clinical and regulatory package to evaluate Sairiyo's patented reformulated enteric coated version of orally bioavailable cepharanthine ("PD-001") as a potential treatment for infectious diseases and oncology in a Phase1 clinical study in Australia. Robert Steen, CEO and Chairman of PharmaDrug commented, "We are extremely excited to reach this milestone in the development of PD-001. With the application package now completed and the corporate subsidiary already set up in Australia, Sairiyo only needs to finalize its agreement with a research hospital in order to submit the application to the relevant regulatory bodies and ethics committees."Sairiyo's wholly-owned subsidiary in Australia, Sairiyo Therapeutics Australia Pty Ltd., will work with an Australian clinical research unit to submit the clinical and regulatory package to the Australian Human Research Ethics Committee for approval to conduct the human clinical study.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and...

Victoria's Chiral Labs to lead development of novel cocaine manufacturing process

Toronto, Ontario--(Newsfile Corp. - March 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC PINK: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that it has initiated work on a project to develop a novel manufacturing method for the commercial-scale manufacture of cocaine to support safe supply programs. PharmaDrug has filed a patent for a novel method of development utilizing biosynthetic chemistry, which it believes will allow for cost effective and efficient Good Manufacturing Practice ("GMP") manufacturing of pharmaceutical grade cocaine at scale.

Toronto, Ontario--(Newsfile Corp. - February 27, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that current board member Dr. David Kideckel has been appointed Chairman of the Board of PharmaDrug replacing Robert Steen who will remain as CEO of the Company.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and...

Company to pursue regulatory filing for Phase I/II clinical study

Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), today announced that it has entered into (i) a marketing and distribution services agreement (the "OTB Agreement") with an arm's length marketing firm, Outside The Box Capital Inc. ("OTBC") to provide marketing services, including digital marketing services through various social media channels to broaden media distribution awareness about the Company; (ii) a services agreement (the "CanaCom Agreement") with CanaCom Group ("CanaCom") to design, develop and execute a company awareness program for the Company; and (iii) a consulting services agreement (the "Candid Agreement") with Candid Capital Corporation ("Candid Capital") to complete a marketing campaign for the Company.

Toronto, Ontario--(Newsfile Corp. - February 8, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce the closing of its previously announced non-brokered private placement raising total gross proceeds of $326,000 (the "Offering").

Toronto, Ontario--(Newsfile Corp. - February 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce a proposed non-brokered private placement offering of units ("Units") to raise total gross proceeds of up to $326,000 (the "Offering").

Toronto, Ontario--(Newsfile Corp. - December 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is providing an update from the CEO to elaborate on the reasoning, vision and strategy for the previously announced and executed acquisition of Securedose Synthetics Inc. ("SecureDose"). (See press release dated November 7, 2023).

Toronto, Ontario--(Newsfile Corp. - November 15, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has closed the previously announced debt restructuring (see press release dated November 7, 2023).

Toronto, Ontario--(Newsfile Corp. - November 8, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), announces that it has granted a total of 6,250,000 stock options ("Options") to purchase common shares of the Company to certain officers, directors and consultants pursuant to the Company's Stock Option Plan. Such Options are exercisable into common shares of the Company at an exercise price of $0.055 per common share for a period of five years from the date of grant. The Options vest immediately.

Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has closed the previously announced acquisition (see press release dated October 27, 2023) of Securedose Synthetics Inc. ("SecureDose"). PharmaDrug acquired all of the issued and outstanding shares of SecureDose by way of a three-cornered amalgamation between Pharmadrug, SecureDose and a wholly-owned subsidiary of PharmaDrug (the "Transaction"). Following completion of the Transaction SecureDose became a wholly-owned subsidiary of PharmaDrug. The Transaction was an arm's length transaction for the purposes of applicable securities laws.

Toronto, Ontario--(Newsfile Corp. - October 27, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has entered into a definitive agreement (the "Acquisition Agreement") dated October 27, 2023 pursuant to which PharmaDrug will acquire all of the issued and outstanding shares of privately-held Securedose Synthetics Inc. ("SecureDose"), to be effected by way of a three-cornered amalgamation between Pharmadrug, SecureDose and a wholly-owned subsidiary of PharmaDrug (the "Proposed Transaction"). Following completion of the Proposed Transaction SecureDose will become a wholly-owned subsidiary of PharmaDrug. It is anticipated that the Proposed Transaction will be completed in early November, 2023. The Proposed Transaction is an arm's length transaction.

Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it will be proceeding with the consolidation of its common shares (the "Common Shares") on the basis of seven (7) pre consolidated Common Shares into one (1) post consolidated Common Share (the "Share Consolidation"). The effective date for the Share Consolidation will be October 24, 2023 and the record date for the Share Consolidation will be October 25, 2023.

Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that, further to its press release dated September 6, 2023, Mr. Daniel Cohen will not be standing for re-election as a director of the Company at the upcoming annual and special meeting of the Company's shareholders to be held on October 13, 2023 at 10:00 a.m. (Toronto time) and he will instead be replaced by Mr. Robert J. Steen, who replaced Mr. Cohen as a director on September 6, 2023. The size of the board will remain at five directors.

Toronto, Ontario--(Newsfile Corp. - September 14, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is pleased to provide an update on the development activities of the Company's patented reformulated enteric coated version of orally bioavailable Cepharanthine (PD-001) as a potential treatment for oncology and infectious disease. The technical transfer and development activities with Genvion Corporation are well-underway in preparation for clinical GMP manufacturing batches of PD-001 to support future filings to Australia's Therapeutic Goods Administration (TGA) and Food and Drug Administration (FDA) in the United States.

Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today the appointment of Robert J. Steen as Chief Executive Officer (CEO) and Chairman of the Board of Directors. Robert will replace Daniel Cohen, who will continue on in an advisory capacity to ensure a proper transition and steady state progress in the cepharanthine program.

Toronto, Ontario--(Newsfile Corp. - July 18, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it has reached an agreement yesterday with PharmaTher Inc. ("PharmaTher"), a wholly-owned subsidiary of PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF), pursuant to which PharmaTher will subscribe for 144,117,647 common shares of PharmaDrug's subsidiary Sairiyo Therapeutics Inc. ("Sairiyo") for $300,000. Following the issuance, PharmaTher will become a 49% shareholder of Sairiyo.

Toronto, Ontario--(Newsfile Corp. - July 5, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it has reached an agreement with the holders of $650,000 principal amount of the Company's convertible debentures to terminate a general security agreement granted by the Company's wholly-owned subsidiary Sairiyo Therapeutics Inc. ("Sairiyo"). As consideration for agreeing to terminate the general security agreement the Company has agreed to issue an aggregate of 5,000,000 common shares in the capital of the Company to the debt holders. The termination of this general security agreement is being completed in conjunction with a proposed strategic investment by an arm's length third party in Sairiyo. Definitive documentation regarding the strategic investment has not yet been entered into and there is no guarantee that such investment will occur. The Company will provide further disclosure regarding the proposed strategic investment once all agreements in respect thereof have been finalized.

Toronto, Ontario--(Newsfile Corp. - May 23, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is announcing that it has appointed David Posner to its Advisory Committee and as a consultant with a mandate for strategic initiatives and corporate restructuring.

Toronto, Ontario--(Newsfile Corp. - Le 17 mai/May 2023) - Effective immediately, Pharmadrug Inc. will be reinstated for trading.

VANCOUVER, BC, May 17, 2023 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - Le 8 mai/May 2023) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.

Toronto, Ontario--(Newsfile Corp. - May 8, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is announcing that the Ontario Securities Commission has issued a "failure to file" cease trade order in respect of the Company's securities under Multilateral Instrument 11-103 Failure-to- File Cease Trade Orders in Multiple Jurisdictions (the "CTO").

VANCOUVER, BC, May 8, 2023 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - April 14, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it has raised $100,000 through the sale of debenture units ("Units"). Each unit is comprised of a $1,000 principal amount convertible secured debenture (a "Debenture") and 20,000 common share purchase warrants (each a "Warrant").

PharmaDrug is positioning to become a leader of DMT-based therapeutics for ocular disease and neuropsychiatric conditions

Toronto, Ontario--(Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company intends to pursue a first-in-human study of its lead development candidate, PD-001, enteric coated cepharanthine-2HCL (for oral administration), in Australia during the second half of 2023.

Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has completed filing a PCT (Patent Cooperation Treaty) application for its lead drug, cepharanthine-2HCL (PD-001) for the treatment of prostate cancer, alone or in combination with standard of care chemotherapeutics, as well as for other indications where the drug has shown efficacy in preclinical studies. This move is expected to build significant value for the Company's investors. Filing of the PCT provides the Company with 18 months to formally elect and pursue patent protection in any of 153 member countries, including countries of strategic interest such as the United States, Canada, Japan and China.

Toronto, Ontario--(Newsfile Corp. - October 4, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has now completed cGMP manufacturing of a multi-kilogram lot of cepharanthine-2HCl for use in the final drug product production of PD-001, its patented, orally bioavailable version of cepharanthine. The Company's capital investment directed at drug synthesis optimization over the last two quarters have resulted in a product yield increase of approximately 30% compared to historical values. Completion of this lot significantly advances the Company's efforts to support pre-clinical and clinical development, including commencement of Phase 2 clinical studies, for parallel indications in oncology and infectious disease. On behalf of the Company, and pending satisfaction of all release testing criteria, Genvion Corporation is scheduled to take receipt of the cGMP drug substance in early November. As the Company's contract development and manufacturing organization, Genvion Corporation has been engaged to complete necessary ICH-compliant stability testing and forced degradation studies in support of future IND filing to the FDA (See press release dated August 19,2022). All downstream manufacturing efforts necessary to produce the orally bioavailable clinical drug product, PD-001 will also be completed by Genvion Corporation.

Toronto, Ontario--(Newsfile Corp. - August 25, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company continues to successfully execute on key objectives related to its multiprong psychedelics research and development strategy by generating potential shareholder value through a diversified approach to foundational research, drug development, and near-term translation into clinical studies. The Company's complimentary efforts in psychedelic research all focus on N,N-Dimethyltryptamine (DMT) and undisclosed analogues thereof. Specifically, PharmaDrug continues to capitalize on its formal engagement and collaborative efforts with leading researchers and translational scientists at Johns Hopkins University (JHU), Center for Psychedelic and Consciousness Research, Terasaki Institute for Biomedical Innovation (TIBI) and University of Michigan, through advancement of drug development efforts, human clinical studies, and strengthening of its patent portfolio.

Toronto, Ontario--(Newsfile Corp. - August 19, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has now completed the significant groundwork, including sourcing and characterization of bulk materials, preparation of reference standards and qualification of all necessary analytical methodologies to support multi-kilogram, cGMP production of cepharanthine-2HCL drug substance for use in the final drug product production of PD-001, its patented, orally bioavailable version of cepharanthine. Completion of this lot, slated for September 2022, significantly advances the Company's efforts to support pre-clinical and clinical development, including to the commencement of potential Phase 2 clinical studies, for parallel indications in oncology and infectious disease. Consistent with these advancements, the Company has formally engaged Genvion Corporation to complete necessary ICH-compliant stability testing and forced degradation studies in support of future IND filings to the U.S. Food and Drug Administration (FDA). On behalf of the Company, Genvion Corporation will take receipt of the cGMP drug substance and complete all manufacturing efforts necessary to produce the orally bioavailable clinical drug product, PD-001.

Toronto, Ontario--(Newsfile Corp. - August 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("Pharmadrug" or the "Company"), is pleased to announce that it has closed the previously announced (see press release dated May 31, 2022) sale of all of the issued and outstanding securities of Pharmadrug Production GmbH ("Pharmadrug GmbH") to Khiron Life Sciences Corp. (TSXV: KHRN) ("Khiron"). Pharmadrug GmbH, is a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union.

Toronto, Ontario--(Newsfile Corp. - August 2, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it has raised $650,000 through the sale of debenture units ("Units"). Each unit is comprised of a $1,000 principal amount convertible secured debenture (a "Debenture") and 20,000 common share purchase warrants (each a "Warrant").

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Kezar Life Sciences (NASDAQ: KZR), Nova Mentis Life Sciences (OTC: NMLSF), Agile Therapeutics (NASDAQ:...

Toronto, Ontario--(Newsfile Corp. - June 16, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that the Company's enteric coated, oral formulation of cepharanthine (PD-001), when combined with paclitaxel, reduces tumor volume and provides improved esophageal cancer tumor growth inhibition. These results support the Company's continued oncology focus for orally administered PD-001 and serve to substantially leverage the FDA-granted orphan drug designation (ODD) for cepharanthine as a therapeutic to treat esophageal cancer.

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Novavax (NASDAQ: NVAX), Stealth BioTherapeutics...

VANCOUVER, BC, May 31, 2022 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce that it has entered into an agreement on May 31, 2022 with Khiron Life Sciences Corp. (TSXV: KHRN) ("Khiron") to sell all of the outstanding securities of Pharmadrug Production GmbH, ("Pharmadrug GMBH") the Company's wholly-owned German subsidiary, a medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union (the "Transaction").

VANCOUVER, BC, May 31, 2022 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - May 27, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the closing of the first tranche (the "First Tranche") of a non-brokered private placement (the "Offering") of units in the capital of the Company (the "Units"). Pursuant to the closing of the First Tranche, the Company issued 7,000,000 Units at a price of $0.04 for aggregate gross proceeds of $280,000.

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: SIGA Technologies (NASDAQ: SIGA), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), GeoVax Labs (NASDAQ:...

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Brickell Biotech (NASDAQ: BBI), Idera Pharmaceuticals...

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PolarityTE, Inc. (NASDAQ: PTE) Veru Inc. (NASDAQ:...

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Veru Inc. (NASDAQ: VERU), PharmaDrug (OTC: LMLLF) (CSE:...

Toronto, Ontario--(Newsfile Corp. - May 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that in collaboration with the Terasaki Institute for Biomedical Innovation (TIBI), has selected its final lead drug candidate from a short list of six N,N-Dimethyltryptamine (DMT) analogue molecules. This decision, based on successful completion of the first phase of the sponsored research agreement, derives from the demonstration of lead candidate superiority as it relates to in vitro potency in two predictive bioassays, a favorable toxicity profile as well as physical, chemical, and metabolic properties necessary to fabricate a proprietary medical device capable of conveniently delivering sub-psychedelic levels of drug to the front of the eye over a sustained period.

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Veru Inc. (NASDAQ: VERU), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Agile Therapeutics (NASDAQ:...

Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK investor conferences, and online events which engage...

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Brickell Biotech (NASDAQ: BBI), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Agile Therapeutics...

Toronto, Ontario--(Newsfile Corp. - April 19, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company's enteric coated, oral formulation of cepharanthine (PD-001), when combined with cabazitaxel, significantly reduces tumor volume and provides improved prostate cancer tumor growth inhibition. Accordingly, the Company has filed a second provisional patent application to support new claims specifically related to the in vivo dosing of cepharanthine in combination with taxane-family members for the treatment of prostate cancer. The current patent application aims to complement the previous provisional patent filing, built around the Company's in vitro study findings, which set forth claims related to the use of cepharanthine plus cabazitaxel and/or other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer.

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Veru Inc. (NASDAQ: VERU), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Clarus Therapeutics (NASDAQ:...

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: PolarityTE, Inc. (NASDAQ: PTE) Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Biodesix, Inc. (NASDAQ:...

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Phio Pharmaceuticals (NASDAQ: PHIO), Veru Inc....

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Sunshine Biopharma, Inc. (NASDAQ: SBFM), PharmaDrug (OTC: LMLLF) (CSE: PHRX), Blue Water Vaccines (NASDAQ:...

Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK investor conferences, which engage an estimated 12...

Toronto, Ontario--(Newsfile Corp. - April 7, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that in collaboration with the Terasaki Institute for Biomedical Innovation (TIBI), it has successfully completed fabrication of a novel medical device capable of delivering sustained, low (sub-psychedelic) quantities of their undisclosed tryptamine-based pharmaceutical to the front of the eye; the intended purpose of which is to potentially lower intraocular pressure (IOP) in patients suffering from glaucoma. Additionally, a head-to-head drug elution study of the Company's three undisclosed DMT-analogue candidates has now been completed and supportive cell-based biocompatibility has been examined for all three candidate molecules. Future in vivo efficacy testing in an accepted model of primary open angle glaucoma (POAG) is currently being planned with the goal of providing all necessary support to file an investigative new drug (IND) application with the United States Food and Drug Administration (the "FDA") to conduct clinical studies.

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: ChargePoint Holdings, Inc. (NYSE: CHPT), PharmaDrug (OTC: LMLLF) (CSE: PHRX) DeepMarkit (OTC: MKTDF)...

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: NIO, Inc. (NYSE:NIO), PharmaDrug (OTC: LMLLF) (CSE: PHRX), NuRAN Wireless (OTC: NRRWF) (CSE: NUR) and SoFi...

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Moderna, Inc. (NASDAQ: MRNA), PharmaDrug (OTC: LMLLF) (CSE: PHRX) Tilray, Inc. (NASDAQ:TLRY) and Vinco...

Toronto, Ontario--(Newsfile Corp. - March 9, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that interim positive findings from its ongoing prostate efficacy study demonstrate that the Company's enteric coated, oral formulation of cepharanthine (PD-001), when combined with cabazitaxel, significantly reduces tumor volume and provides improved prostate cancer tumor growth inhibition when administered with cabazitaxel. These interim results, provided to the Company on the final day of study dosing will be used to strengthen claims in its recently submitted provisional patent application which sets forth claims related to the use of cepharanthine plus cabazitaxel and/or other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer.

Toronto, Ontario--(Newsfile Corp. - February 23, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has successfully completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary open angle glaucoma (POAG). Following this successful outcome, the Company, in collaboration with the Terasaki Institute for Biomedical Innovation (TIBI), has initiated fabrication activities necessary to produce a novel medical device capable of delivering sustained, low (sub-psychedelic) quantities of their undisclosed tryptamine-based pharmaceutical to the front of the eye. The Company intends to use the current results in combination with several planned upcoming in vitro studies to elect its final development candidate. Future in vivo efficacy testing in an accepted model of POAG is currently being planned with the goal of providing all necessary support to file an investigative new drug (IND) application with the FDA to conduct clinical studies.

Toronto, Ontario--(Newsfile Corp. - February 1, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has filed a US provisional patent application which details the novel synergistic combination of cepharanthine (PD-001) and cabazitaxel on prostate cancer growth inhibition and also sets forth claims related to the use of PD-001, cabazitaxel and/or other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer.

Establishing cGMP supply for IND-enabling and up to Phase 2 clinical studies for PD-001 oral formulation for esophageal cancer and mild to moderate COVID-19

Toronto, Ontario--(Newsfile Corp. - January 24, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company's Chairman and CEO Daniel Cohen will be presenting at Wall Street Reporter's "Next Super Stock" livestream conference on January 25, 2022.

Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announces that it has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program.

Toronto, Ontario--(Newsfile Corp. - January 13, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announces that Mr. Robert Schwartz has resigned from the board of directors of the Company (the "Board"), and the Board has accepted his resignation. The Company thanks Mr. Schwartz for his valuable contributions and wishes him every success in his future endeavors.

Toronto, Ontario--(Newsfile Corp. - December 13, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, pleased to announce the addition of Dr. Cindy Hutnik to its scientific and clinical advisory board. Dr. Hutnik will assist the Company in its ongoing efforts to develop N,N-dimethyltryptamine ("DMT") and other related tryptamine analogues as a potential treatment for glaucoma.

Toronto, Ontario--(Newsfile Corp. - November 30, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the successful completion of its Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA), for which a pre-IND briefing package and meeting request letter was submitted in September 2021. The FDA has provided written responses to the Company regarding its clinical development plan for PD-001, a patented enteric-coated formulation of cepharanthine, as a potential oral antiviral pill for COVID-19. PharmaDrug believes the written response provides a path to agreements on IND-enabling studies, the design of a Phase 1/2 clinical study, and the overall clinical development plan to move PD-001 forward as an oral treatment for COVID-19. By extension, the FDA guidance also provides important insights on advancing PD-001 as a potential treatment for oncology indications as part of the Company's ongoing strategy of targeting rare and life-threatening conditions. The Company continues to focus on completing the remaining IND-enabling studies to support future clinical studies in 2022.

Toronto, Ontario--(Newsfile Corp. - November 18, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce positive research results for their preclinical cancer study which evaluated the effectiveness of cepharanthine-2HCl alone, or when used in combination with standard of care (SoC) chemotherapy on four undisclosed cancers. The Company is now focused on advancing to IND-enabling studies to support future FDA clinical studies in 2022.

Toronto, Ontario--(Newsfile Corp. - November 1, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its 100% owned cannabis and controlled substance distributor Pharmadrug Production GmbH ("Pharmadrug Production") has expanded its product offering with a goal to increase its pharmacy network and sales volume as it prepares for the significantly increased potential of cannabis adult use legalization in Germany.

Toronto, Ontario--(Newsfile Corp. - October 20, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has qualified for trading on the OTCQB Venture Market (the "OTCQB") operated by the OTC Markets Group Inc. The Company's common shares commenced trading yesterday on the OTCQB under the symbol "LMLLF." The Company's common shares will continue to trade on the Canadian Securities Exchange (the "CSE") under the symbol "PHRX".

Toronto, Ontario--(Newsfile Corp. - October 15, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce interim positive results for their preclinical cancer study which evaluated the effectiveness of cepharanthine-2HCl alone, or when used in combination with standard of care (SoC) chemotherapy.

Toronto, Ontario--(Newsfile Corp. - September 28, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has been granted a Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the clinical development of its patented enteric-coated formulation of cepharanthine (PD-001), an oral antiviral pill as a potential treatment for mild-moderate COVID-19. The Company submitted a briefing package to the FDA, Office of Infectious Diseases, Center for Drug Evaluation and Research for cepharanthine and awaits further feedback on its proposed path toward human clinical development. The pre-IND meeting is a critical step in the US regulatory approval process that is meant to develop mutual understanding and agreement between the FDA and the Company regarding content required to assess manufacturing, toxicology, pre-clinical studies, clinical trials design, and rationale to support subsequent human clinical trials. PharmaDrug anticipates a written response to its pre-IND briefing package by late-November 2021.

Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division is launching its own premium blend of functional mushrooms. MycoWe℞ Infinite will initially debut for sale in the United States before also being made available through Super Smart's ecommerce platform in Europe. The first commercial lot of product has already been manufactured and the Company expects to start shipping orders mid-October.

Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that David Kideckel will be joining the board effective immediately.

Toronto, Ontario--(Newsfile Corp. - August 25, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a Clinical Trial Agreement with The Johns Hopkins University (JHU) to conduct a clinical study comparing acute and enduring psychological and neural effects of N,N-Dimethyltryptamine (DMT) and an undisclosed, potently active comparator molecule. The principal investigator, Dr. Frederick S. Barrett, PhD, Associate Professor of Psychiatry and Behavioral Sciences, will be supported by Co-investigators Dr. Sandeep Nayak and Dr. Roland Griffiths; all from the JHU Center for Psychedelic and Consciousness Research.

Toronto, Ontario--(Newsfile Corp. - August 6, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that Harbourside CPA, LLP (the "Successor Auditor") has been appointed as the Company's auditor effective as of August 6, 2021 until the closing of the next Annual General Meeting. Further details relating to the change of auditor can be found in the Company's press release dated July 12, 2021.

Toronto, Ontario--(Newsfile Corp. - August 5, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that PharmaDrug has entered into a sponsored research agreement with the Terasaki Institute to develop a novel ocular drug delivery platform that aims to deliver psychedelic and tryptamine-based pharmaceuticals, such as N, N-dimethyltryptamine ("DMT"), for eye diseases.

Toronto, Ontario--(Newsfile Corp. - Le 26 juillet/July 2021) - Pharmadrug Inc. has announced a symbol change to PHRX. Shares will begin trading under the new symbol on August 3, 2021.